# US 2011/0212454 A1 · Assay for Telomerase Activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0212454 A1
- Document ID: US20110212454A1
- Status: Published application
- Kind: A1
- Application number: 13/035,469
- Filed: 2011-02-25
- Published: 2011-09-01
- Earliest claimed: 2010-02-26
- Assignees: Geron Corporation
- Inventors: Zhu Zhen Pirot
- Web page: https://patentgrep.com/patent/US20110212454A1

## CPC

- C12Q 1/48: involving transferase
- G01N 2333/91245: Nucleotidyltransferases (2.7.7)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention is directed to methods for determining the level of telomerasc reverse transcriptase activity in mammalian cells.

## Claims

### Claim 1

A method for detecting a presence or an amount of telomerase activity, comprising:
(a) combining in a reaction vessel (1) an active telomerase ribonucleoprotein enzyme complex bound to a solid support by an anti-telomerase antibody, (2) a first primer, which is suitable as a telomerase substrate, and (3) a plurality of nucleoside triphosphates to form a reaction mixture, and incubating the reaction mixture under conditions to extend the first primer to produce an extension product; and (b) qualitatively or quantitatively detecting the extension product and correlating the detection with the presence or amount of telomerase activity.

### Claim 2

A method for detecting a presence or an amount of telomerase activity, comprising:
(a) binding an active telomerase ribonucleoprotein enzyme complex to a solid support with an antibody specific for the telomerase ribonucleoprotein enzyme complex,
(a) combining in a reaction vessel (1) telomerase ribonucleoprotein enzyme complex bound to the solid support, (2) a first primer, which is suitable as a telomerase substrate, and (3) a plurality of nucleoside triphosphates to form a reaction mixture, and incubating the reaction mixture under conditions to extend the first primer to produce an extension product; and
(b) qualitatively or quantitatively detecting the extension product and correlating the detection with the presence or amount of telomerase activity

### Claim 3

A method for evaluating the biological response of a mammalian biological system exposed to a telomerase modulator comprising:
(a) combining in a reaction vessel (1) an active telomerase ribonucleoprotein enzyme complex from the biological system bound to a solid support by an anti-telomerase antibody, (2) a first primer, which is suitable as a telomerase substrate, and (3) a plurality of nucleoside triphosphates to form a reaction mixture, and incubating the reaction mixture under conditions to extend the first primer to produce an extension product; and
(b) qualitatively or quantitatively detecting the extension product and correlating the amount of extension product with the amount of telomerase activity;
(c) comparing the level of telomerase activity after administration of the modulator to the standard telomerase activity to determine the biological response of the subject.

### Claim 4 (depends on 1)

The method of claim 1 wherein the antibody is a polyclonal mixture of antibodies including antibodies specific for telomerase ribonucleoprotein enzyme complex.

### Claim 5 (depends on 1)

The method of claim 1 wherein the antibody is specific for a 10-19 amino acid peptide sequence from the sequence ARPAEEATSLEGALSGTRH (SEQ ID NO:2).

### Claim 6 (depends on 1)

The method of claim 1 wherein the first primer is labeled.

### Claim 7 (depends on 6)

The method of claim 6 wherein the label is selected from the group consisting of a radioactive molecule, a fluorescent molecule, a phosphorescent molecule, a ligand for a receptor, and anchor group selected from biotin, avidin or streptavidin.

### Claim 8 (depends on 7)

The method of claim 7 further comprising a step wherein the extension products are immobilized on a solid phase via an anchor group.

### Claim 9 (depends on 8)

The method of claim 8 wherein the anchor group is biotin and the solid phase is coated with avidin and/or streptavidin.

### Claim 10 (depends on 1)

The method of claim 1 further comprising a step wherein the extension products are amplified to produce amplification products and qualitatively or quantitatively detecting the amplification products to qualitatively or quantitatively detect the extension product.

### Claim 11 (depends on 10)

The method of claim 10 wherein the extension products are amplified by adding to the reaction mixture a second primer comprising a sequence complementary to a telomeric repeat and extending the second primer to produce amplification products.

### Claim 12 (depends on 10)

The method of claim 10 wherein the amplification products are detected via a labeled probe bound to the second primer.

### Claim 13 (depends on 12)

The method of claim 12 wherein the label is selected from the group consisting of a radioactive molecule, a fluorescent molecule, a phosphorescent molecule, a ligand for a receptor, and an anchor group selected from biotin, avidin or streptavidin.

### Claim 14 (depends on 10)

The method of claim 10 further comprising the step wherein the amplification products are immobilized on a solid phase via an anchor group.

### Claim 15 (depends on 14)

The method of claim 14 wherein the anchor group is biotin and the solid phase is coated with avidin and/or streptavidin.

### Claim 16 (depends on 10)

The method of claim 10 wherein the amplification product is labeled with an intercalating dye selected from the group consisting of a fluorescent molecule.

### Claim 17 (depends on 10)

The method of claim 10 wherein the first primer lacks a telomeric repeat sequence

### Claim 18 (depends on 17)

The method of claim 17 wherein the first primer lacking a telomeric repeat sequence is 5′-AATCCGTCGAGCAGAGTT-3′ (SEQ ID NO:1).

### Claim 19 (depends on 11)

The method of claim 11 wherein the second primer comprises a non-telomeric repeat sequence at the 5′-end of said primer.

### Claim 20 (depends on 11)

The method of claim 11 wherein the second primer is 5′-CCCTTACCCTTACCCTTACCCTAA-3 (SEQ ID NO:4), 5′-GCGCGGCTAACCCTAACCCTAACC-3′ (SEQ ID NO:5) or 5′-GCGCGGCTTACCCTTACCCTTACCCTAACC-3′ (SEQ ID NO:6).

### Claim 21 (depends on 1)

The method of any of claim 1 wherein further comprising normalizing the level of telomerase activity in the cell extract relative to the amount of RNA or protein in the cell extract.

### Claim 22 (depends on 3)

The method of claim 3 wherein the mammalian biological system is a cell or tissue extract.

### Claim 23 (depends on 22)

The method of claim 22 wherein the cells are cancer cells, skin cells, hair follicle cells, or blood cells.
